QRX-3 for Chronic Kidney Disease

(NAD agent Trial)

Not yet recruiting at 1 trial location

Age: 18+

Sex: Any

Trial Phase: Phase 2 & 3

Sponsor: Ebima Clifford Okundaye

Disqualifiers: Rapid decline, Symptomatic failure, others

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

Duration: 1 year

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new drug, QRX-3, to determine if it can improve kidney function in people with chronic kidney disease (CKD). CKD affects millions globally and often reduces quality of life and life expectancy. Participants will take either QRX-3 or a placebo (a pill with no active ingredients) to compare results. Suitable candidates have CKD with declining kidney function, but not too rapidly. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Is there any evidence suggesting that QRX-3 is likely to be safe for humans?

Research has shown that QRX-3 underwent testing in earlier human trials, and these studies indicate its use without major safety concerns. This treatment aims to enhance kidney function by boosting the energy supply to cells.

QRX-3 increases a key molecule called NAD+ in the body, which may improve kidney function. Previous trials did not report serious side effects, suggesting it is generally well-tolerated. However, as with any treatment, minor side effects may occur. Discuss these with the study team before deciding to join the trial. ^{1 2 3 4 5}

Why do researchers think this study treatment might be promising?

Unlike most treatments for chronic kidney disease, which often focus on controlling symptoms like high blood pressure and diabetes, QRX-3 offers a fresh approach. Researchers are excited because QRX-3 targets the root cause of kidney damage by reducing inflammation and protecting kidney cells, potentially slowing disease progression. This oral medication, taken as two capsules twice daily, might provide a more direct and convenient treatment option compared to injections or dialysis. If successful, QRX-3 could represent a significant advancement in chronic kidney disease care, offering hope for improved kidney function and quality of life.

What evidence suggests that QRX-3 might be an effective treatment for chronic kidney disease?

Research has shown that QRX-3 could be promising for treating chronic kidney disease (CKD). This trial will evaluate QRX-3, which improves kidney function by enhancing a process important for cell energy and repair. In studies, patients using QRX-3 demonstrated better kidney function, with improvements in their glomerular filtration rate, a measure of kidney performance. QRX-3 aims to prevent kidney damage by supporting the mitochondria, the energy centers in cells. Early findings suggest it may slow CKD progression, offering hope for better disease management. Participants in this trial will receive either QRX-3 or a placebo to assess its effectiveness. ^{1 4 5 6 7}

Are You a Good Fit for This Trial?

This trial is for individuals with chronic kidney disease (CKD) who have shown a slow decline in kidney function over the past year, specifically less than a 20% drop in eGFR. Participants must have an eGFR under 60ml/min and no signs of rapid kidney failure or acute conditions superimposed on their CKD.

Inclusion Criteria

Negative Serology markers for CKD etiology

Provider perceived adherence to study follow up

Rate of decline of eGFR over the last one year of less than 20%

Exclusion Criteria

My kidney function has dropped more than 20% in the last year.

I am experiencing symptoms of kidney failure.

I am experiencing sudden kidney failure.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive QRX-3 or placebo for the prevention and treatment of chronic kidney disease progression

1 year

Regular visits as per study protocol

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• QRX-3

Trial Overview

The study tests QRX-3, a new drug aimed at improving kidney function and slowing down the progression of CKD. The goal is to see if this medication can prevent patients from reaching stages that require dialysis or lead to renal failure.

How Is the Trial Designed?

Group I: intervention Active Control 1 Intervention

QRX-3 - two capsules orally twice daily

Group II: placebo Placebo Group 1 Intervention

placebo pill - one capsule orally twice daily

Who Is Running the Clinical Trial?

Ebima Clifford Okundaye

Lead Sponsor

Trials

1

Recruited

2,400+

Citations

1.

clinicaltrials.gov

clinicaltrials.gov/study/NCT06866236

Study Details | NCT06866236 | Use of New Drug QRX-3 for ...

In this study the investigators will evaluate the effect of intervention with this novel drug therapy on chronic kidney disease CKD population with slowly ...

2.

researchgate.net

researchgate.net/publication/374048507_Outcome_of_use_of_a_novel_Modulator_of_Oxidative_Phosphorylation_on_kidney_function_in_patients_with_Chronic_Kidney_disease/fulltext/650b027682f01628f0344699/Outcome-of-use-of-a-novel-Modulator-of-Oxidative-Phosphorylation-on-kidney-function-in-patients-with-Chronic-Kidney-disease.pdf

Outcome-of-use-of-a-novel-Modulator-of-Oxidative- ...

In this article we studied the effect of utilizing a novel drug QRX3 , a promoter of NAD/NAD+ oxidative phosphorylation pathway and its effect.

3.

clinicaltrials.gov

clinicaltrials.gov/study/NCT07150338

Study Details | NCT07150338 | Outcome of Use of a Novel ...

In this study the investigators evaluate the effect of intervention with this novel drug therapy on a chronic kidney disease CKD population with ...

4.

centerwatch.com

centerwatch.com/clinical-trials/listings/NCT06866236/use-of-new-drug-qrx-3-for-prevention-and-treatment-of-chronic-kidney-disease-progression

Use of New Drug QRX-3 for Prevention and Treatment ...

QRX-3 is a formulated novel drug designed to supply and optimize NAD+ mitochondrial availability and prevent this nephron loss . In this study ...

5.

connect.careboxhealth.com

connect.careboxhealth.com/en-US/trial/listing/580555

Use of New Drug QRX-3 for Prevention and Treatment of ...

Primary outcome measures ; Outcome measure. change in Glomerular filtration rate ; Measure description. change percentage in kidney function level measured with ...

6.

clinicaltrials.gov

clinicaltrials.gov/study/NCT06948292

NCT06948292 | Role of QRX-3 in Chronic Kidney Disease ...

Also called a data safety and monitoring board, or DSMB. Early Phase 1 ... Role of QRX-3 in Chronic Kidney Disease Patients in Outpatients Clinics (QRX-3 in CKD).

7.

withpower.com

withpower.com/trial/phase-2-and-3-kidney-diseases-9-2025-ed6f9

QRX-3 for Chronic Kidney Disease (NAD agent Trial)

Prior Safety DataThis treatment has passed at least one previous human trial. What You Need to Know Before You Apply. What is the purpose of this trial ...